Viewing Study NCT04882904


Ignite Creation Date: 2025-12-24 @ 9:21 PM
Ignite Modification Date: 2025-12-27 @ 8:15 PM
Study NCT ID: NCT04882904
Status: RECRUITING
Last Update Posted: 2025-12-05
First Post: 2021-03-11
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
Sponsor: Centre Hospitalier Universitaire de Liege
Organization:

Study Overview

Official Title: Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.

The investigators have planned to assess patient every three months for a year. On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores.

They will perform few tests ( 6-minutes walk test (6MWT), dynamometric measure, electromyography, Edinburgh Cognitive and Behavioural ALS Screen ) and will answer to some questionaires (dysphagia handicap scale, ALS-SFR-r).

After each visit, participants will wear Actimyo for one month daily.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: